Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
27,786,246
-
Share change
-
+23,817,439
-
Total reported value
-
$361,216,517
-
Put/Call ratio
-
27%
-
Price per share
-
$13.00
-
Number of holders
-
63
-
Value change
-
+$310,785,532
-
Number of buys
-
47
-
Number of sells
-
13
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q2 2020
As of 30 Jun 2020,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,786,246 shares.
The largest 10 holders included
BVF INC/IL, RTW INVESTMENTS, LP, Redmile Group, LLC, Logos Global Management LP, ADAGE CAPITAL PARTNERS GP, L.L.C., Ikarian Capital, LLC, RENAISSANCE TECHNOLOGIES LLC, Vivo Capital, LLC, VANGUARD GROUP INC, and RA CAPITAL MANAGEMENT, L.P..
This page lists
63
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.